Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Pipeline Review, H1 2018

  • ID: 4479937
  • Report
  • 56 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • MORE
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Pipeline Review, H1 2018

Summary:

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

The latest report Kinesin Like Protein KIF11 - Pipeline Review, H1 2018, outlays comprehensive information on the Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Kinesin spindle protein (KSP) is a member of the kinesin superfamily of microtubule-based motors. It plays an important role in mitosis.

It mediates centrosome separation and bipolar spindle assembly and maintenance. Inhibition of KSP function leads to cell cycle arrest at mitosis with the formation of monoastral microtubule arrays and ultimately cell death. The molecules developed by companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively.

Report covers products from therapy areas Oncology and Immunology which include indications Ovarian Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Lymphoma, Melanoma and Non-Small Cell Lung Cancer.

Furthermore, this report also reviews key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics development with respective active and dormant or discontinued projects.

Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11)
  • The report reviews Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Overview

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Companies Involved in Therapeutics Development

4SC AG

Alnylam Pharmaceuticals Inc

Kyowa Hakko Kirin Co Ltd

Merck & Co Inc

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Drug Profiles

4SC-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-VSP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8267 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Eg5 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KSP for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRI-35566 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Dormant Products

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Discontinued Products

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Product Development Milestones

Featured News & Press Releases

Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO

Dec 09, 2014: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme

Jul 29, 2013: Motor Protein Revs Up Cell Division

Jun 06, 2013: Leukemia & Lymphoma Society Honors Ohi’s Research

Jan 31, 2013: Tekmira Announces Publication Of Data On LNP Technology In Journal Cancer Discovery

Jan 30, 2013: Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP For Treatment Of Liver Cancer

Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment

Jun 04, 2012: Alnylam Presents Results From Phase I Extension Study Of ALN-VSP At ASCO 2012 Annual Meeting

Mar 14, 2012: Tekmira Provides Update On Progress In USPTO Patent Interference Proceedings Related To Alnylam's ALN-VSP

Aug 01, 2011: Alnylam Completes Phase I Trial Of ALN-VSP In Liver Cancer

Jun 04, 2011: Alnylam Presents Phase I Data For ALN-VSP At American Society Of Clinical Oncology Meeting

May 18, 2011: Alnylam's ALN-VSP Abstract Published By American Society Of Clinical Oncology

Mar 31, 2011: Alnylam Completes Enrollment In ALN-VSP Phase I Clinical Trial

Jan 04, 2011: Alnylam Reports Positive Data From ALN-VSP Phase I Liver Cancer Trial

Nov 10, 2010: Alnylam Presents Additional Interim Phase I Data For ALN-VSP For Treatment Of Liver Cancer

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by 4SC AG, H1 2018

Pipeline by Alnylam Pharmaceuticals Inc, H1 2018

Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • Alnylam Pharmaceuticals Inc
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll